Xylo

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Elkedonia

This biotechnology company develops neuroplastogen treatments for patients suffering from treatment-resistant depression and other neuropsychiatric disorders.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Helus Pharma

This pharmaceutical company develops serotonergic agonists and psychedelic medicines to treat patients with depression, anxiety and other mental health conditions.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.